Last reviewed · How we verify
Experimental dose: modified XELOX + sintilimab
Modified XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotherapy while simultaneously unleashing the immune system to attack tumors.
Modified XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotherapy while simultaneously unleashing the immune system to attack tumors. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial indication).
At a glance
| Generic name | Experimental dose: modified XELOX + sintilimab |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy + PD-1 inhibitor |
| Target | PD-1 (sintilimab component); DNA/thymidylate synthase (XELOX component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
XELOX is a combination chemotherapy regimen (capecitabine and oxaliplatin) that damages cancer cell DNA and inhibits proliferation. Sintilimab is a humanized monoclonal antibody that blocks PD-1 on T cells, removing the immune checkpoint that allows tumors to evade immune surveillance. Together, the chemotherapy primes the immune system while sintilimab enhances T-cell activation against tumor antigens.
Approved indications
- Gastric or gastroesophageal junction cancer (Phase 3 trial indication)
Common side effects
- Neutropenia
- Anemia
- Nausea/vomiting
- Diarrhea
- Hand-foot skin reaction
- Immune-related adverse events (fatigue, rash, hepatotoxicity)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |